Bomedus GmbH, a Bonn, Germany-based medical startup, closed €2.5m Series B funding round.
Backers included new investors NRW.Bank and private investor Dr. Christoph Schug. Other shareholders are the High-Tech Gründerfonds (HTGF), the Pre-Seed Fund (PSF) and Prof. Dr. Andreas Hoeft, Bonn.
The company intends to use the funds to extend the product portfolio and to foster commercialization internationally. The new capital will be mainly used to launch further medical products to treat chronic pain and to foster further clinical trials.
Led by Dr. Johannes Weigl, founder and CEO, Bomedus is an innovative healthcare company that develops medical devices that decrease effectively chronical pain of patients. The whole product portfolio is based on the mechanism of an electro-therapeutic method, the so-called Small Fiber Matrix Stimulation (SFMS). The technology enables patients to achieve a modulation of the pathologically altered neuronal impulses non-invasively, which has emerged trough the course of chronic pain.
The company is a spin-off of the University Clinic of Bonn.